VAM
BNGO icon

Verity Asset Management’s Bionano Genomics BNGO Stock Holding History

Verity Asset Management’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$33K Sell
21
-7
-25% -$9.45K 0.02% 204
2021
Q4 		$51K Buy
+28
New +$74.9K 0.03% 198

Other funds holding BNGO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return

Verity Asset Management's BNGO Position: Q1 2022 in Review

Verity Asset Management reduced its Bionano Genomics (BNGO) stake by 25% in Q1 2022, selling an estimated $9.45K and leaving 21 shares worth $33K. The position accounts for 0.02% of the portfolio, ranked #204.

Verity Asset Management first reported a position in BNGO in Q4 2021 and has held it in 2 quarters since. The position peaked at $51K in Q4 2021. 148 funds tracked by Wall St. Rank hold BNGO as of Q1 2022.

  • Verity Asset Management held 21 shares of Bionano Genomics worth $33K as of Q1 2022.
  • Verity Asset Management sold 7 Bionano Genomics shares in Q1 2022, an estimated $9.45K.
  • Bionano Genomics made up 0.02% of Verity Asset Management's portfolio in Q1 2022, its #204 holding.
  • Verity Asset Management first reported a position in Bionano Genomics in Q4 2021 and has held it in 2 quarters since.
  • Verity Asset Management's Bionano Genomics position peaked at $51K in Q4 2021.
  • 148 funds tracked by Wall St. Rank held Bionano Genomics as of Q1 2022.

Based on Verity Asset Management's 13F filing for Q1 2022, filed 12 May 2022.